To the Editor Steenbruggen et al1 shared a 20-year follow-up of a phase 3 randomized clinical trial of high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant in patients with high-risk breast cancer and 4 or more involved axillary lymph nodes. The authors’ conclusion suggests that selected subgroups may benefit from this treatment, highlighting a 14.6% improvement in 20-year overall survival estimates with HDCT in the predefined subgroup for patients with 10 or more involved axillary lymph nodes. The authors are to be commended for their efforts in reporting the long-term results of this trial. However, the conclusions generate questions in both statistical interpretation and generalized application.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ertz-Archambault N, Northfelt DW, Sonbol MB. High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer. JAMA Oncol. Published online June 04, 2020. doi:10.1001/jamaoncol.2020.1646
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: